ClinicalTrials.gg
CompletedNCT01380535Updated Feb 19, 2020Results posted

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

An Early Phase 1 interventional study of ECP Methoxsalen and Standard of Care in Chronic Graft Versus Host Disease, sponsored by Mallinckrodt. Completed at 32 sites in 8 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by Mallinckrodt · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 71 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Enrollment
108th of 260
60 · median 45
Started
2011
with 14 others
Phase 1
30 of 300
5 open now
Registered
87th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 108th largest by enrollment of the 260 interventional ones that give a count, is one of 15 that started in 2011, is one of 30 in phase 1, and was the 87th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.

Extracorporeal photopheresis (ECP) is a fairly new procedure for cGVHD. The participant gets a port to hook up to a machine. The machine removes the white blood cells, mixes them with a light-sensitive drug, shines light on it, and puts all the blood back in.

This study will find out if patients respond better if they get ECP with methoxsalen, in addition to the pills normally used to treat cGVHD.

Read the detailed description

The investigation of extracorporeal photopheresis (ECP) plus standard of care (SoC) (SoC+ECP) in chronic graft-versus-host disease (cGVHD) within prospective, randomized clinical studies is limited, despite its frequent clinical use.

This phase 1/pilot study was the first randomized, prospective study to investigate ECP use as first-line therapy in cGVHD, based on the 2015 National Institutes of Health (NIH) consensus criteria for diagnosis and response assessment.

Adult patients with new-onset (≤3 years of hematopoietic stem cell transplantation) moderate or severe cGVHD were randomized 1:1 to 26 weeks of SoC+ECP vs SoC (corticosteroids and cyclosporine A/tacrolimus) between 2011 and 2015. The primary endpoint was overall response rate (ORR), defined as complete or partial response, at week 28 in the intention-to-treat population (ITT).

03

Conditions studied

  • Chronic Graft Versus Host Disease

Keywords

  • Extracorporeal photopheresis therapy
  • Methoxsalen
  • cGVHD
  • hematopoietic stem cell transplantation
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for inclusion in this trial, the patient must have moderate to severe chronic [defined by the National Institutes of Health (NIH) 2015 Consensus Criteria] that started within 3 years after hematopoietic stem cell transplantation ().

Exclusion criteria

Exclusion Criteria:

  • Is intolerant to or hypersensitive to methoxsalen
  • Received certain treatments during time periods disallowed by protocol
  • Has infections and/or requires treatment that (per protocol or in the opinion of the investigator) might compromise:

    1. safety and well-being of participant or offspring
    2. safety of study staff
    3. analysis of results
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ECP Methoxsalen + Standard of Care

    Participants receive methoxsalen administered via ECP in addition to standard of care

    Drug: ECP Methoxsalen · Drug: Standard of Care

  • Active comparator
    Standard of Care

    Participants receive standard of care only

    Drug: Standard of Care

Interventions

  • Methoxsalen delivered by ECP

    Also known as: Uvadex, Extracorporeal photopheresis (ECP)

  • DrugStandard of Care

    Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)

    Also known as: Reference therapy

06

What researchers measure

Primary outcomes

  1. Number of Participants With an Overall Response at Week 28

    Participants with overall response included those with partial response or complete response, according to study staff who did not know which treatment they received (blinded assessment).

    Time frame: Week 28

07

Results

Posted Oct 29, 2019
Limitations and caveats
Long term follow-up (LTFU) safety data were provided to health authorities in safety reports; not the 28-week protocol. LTFU pre-specified outcome measures previously entered in error were removed.

Participant flow

Patients were enrolled in Austria, France, Germany, Italy, Hungary, Spain, the United Kingdom, and the United States. Enrollment started in November 2011, and the last patient visit occurred in March 2015.

Participant flow — Overall Study
MilestoneECP Methoxsalen + SoCStandard of Care (SoC)
Started2931
Baseline population2931
Safety population2828
Intent-to-treat population2924
Completed2216
Not completed715
Withdrew: Adverse event33
Withdrew: Death30
Withdrew: Study site closed05
Withdrew: Withdrawal by subject12
Withdrew: Protocol violation02
Withdrew: Lack of efficacy03

Outcome measures

PrimaryNumber of Participants With an Overall Response at Week 28

Participants with overall response included those with partial response or complete response, according to study staff who did not know which treatment they received (blinded assessment).

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number of Participants With an Overall Response at Week 28
ParticipantsECP Methoxsalen + SoCStandard of Care (SoC)
Number of Participants With an Overall Response at Week 282014
Statistical analysis
  • ECP Methoxsalen + SoC vs Standard of Care (SoC) · Fisher Exact · p = 0.373

Adverse events

Collected over Treatment emergent adverse events were recorded from the start of treatment through Week 28.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ECP Methoxsalen + SoC4/29 (13.8%)8/28 (28.6%)26/28 (92.9%)
Standard of Care (SoC)0/31 (0%)9/28 (32.1%)24/28 (85.7%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventECP Methoxsalen + SoCStandard of Care (SoC)
SepsisInfections and infestations2/281/28
MyopathyMusculoskeletal and connective tissue disorders0/282/28
Cardiac FailureCardiac disorders0/281/28
Thyroiditis subacuteEndocrine disorders1/280/28
Graft versus host disease in liverImmune system disorders0/281/28
Bronchopulmonary aspergillosisInfections and infestations1/280/28
Cytomegalovirus infectionInfections and infestations1/280/28
Escherichia infectionInfections and infestations1/280/28
Escherichia sepsisInfections and infestations1/280/28
Herpes simplexInfections and infestations0/281/28
Most frequent other events
Showing 10 of 44
Most frequent other events
EventECP Methoxsalen + SoCStandard of Care (SoC)
HypertensionVascular disorders9/284/28
CoughRespiratory, thoracic and mediastinal disorders6/281/28
FatigueGeneral disorders5/281/28
Back painMusculoskeletal and connective tissue disorders2/285/28
DyspnoeaRespiratory, thoracic and mediastinal disorders5/282/28
ThrombocytopeniaBlood and lymphatic system disorders2/284/28
DiarrhoeaGastrointestinal disorders1/284/28
Oedema peripheralGeneral disorders2/284/28
PyrexiaGeneral disorders0/284/28
Gamma-glutamyltransferase increasedInvestigations4/283/28

Baseline characteristics

All participants enrolled and included in the safety analysis set

Age, Customized
Age, Customized(Participants)ECP Methoxsalen + SoCStandard of Care (SOC)Total
18-44 years81018
45-64 years191938
65 years and over224
Sex: Female, Male
Sex: Female, Male(Participants)ECP Methoxsalen + SoCStandard of Care (SOC)Total
Female71320
Male221840
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ECP Methoxsalen + SoCStandard of Care (SOC)Total
Hispanic or Latino224
Not Hispanic or Latino242448
Unknown or Not Reported358
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ECP Methoxsalen + SoCStandard of Care (SOC)Total
White222446
Black202
Asian000
Other112
Not Collected4610
Region of Enrollment
Region of Enrollment(participants)ECP Methoxsalen + SoCStandard of Care (SOC)Total
Austria336
Hungary448
United States6612
Italy033
United Kingdom112
France4610
Germany11718
Spain011
08

Study locations

32 sites
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Indiana Blood and Marrow Transplantation Research
    Indianapolis, Indiana 46237, United States
  • Tulane University Health Sciences Center, 1430 Tulane Avenue, Rm 7551,
    New Orleans, Louisiana 70112, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York Presbyterian Hospital
    New York, New York 10065, United States
  • Stony brook university medical Center
    Stony Brook, New York 11794, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Medical City Dallas Hospital,Transplant center
    Dallas, Texas 75230, United States
  • Parkland Memorial Hospital
    Dallas, Texas 75235, United States
  • Methodist healthcare system of san Antonio
    San Antonio, Texas 78229, United States
  • General Hospital of Vienna (Medical University of Vienna)
    Vienna, Austria
  • Hopital Saint Antoine
    Saint Antoine, Paris 75571, France
  • CHU de Nantes
    Nantes, France
  • Hospital Saint Louis
    Paris, France
  • Universitätsklinik Köln
    Cologne, 50937, Germany
  • Universitäts-Klinikum Carl Gustav Carus
    Dresden, 01309, Germany
  • Universitatsklinikum Erlangen
    Erlangen, 91054, Germany
  • Universitätsklinikum Essen
    Essen, 45122, Germany
  • Universitatskrankenhaus Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Universitätsklinikum Leipzig AöR
    Leipzig, 04103, Germany
  • Universitätklinikum Mannheim
    Mannheim, 68167, Germany
  • Medizinische Universitatsklinik
    Munchen, 81377, Germany
  • Uniklinik für Kinder und Jugendmedizin
    Tubingen, 72076, Germany
  • Egyesített Szent István és Szent László Kórház, Gyáli út 5-7,
    Budapest, 1097, Hungary
  • A.O.U. Policlinico- Vittorio Emanuele
    Catania, Italy
  • Universita de Genova - Ospedale S. Martino
    Genova, Italy
  • Hospital Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Kings College Hospital
    London, Greater London SE5 9RS, United Kingdom
  • University of Birmingham: Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • Royal Marsden Hospital
    London, United Kingdom
09

References and documents

Publications

  • Jagasia M, Scheid C, Socie G, Ayuk FA, Tischer J, Donato ML, Batai A, Chen H, Chen SC, Chin T, Boodee H, Mitri G, Greinix HT. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019 Jul 23;3(14):2218-2229. doi: 10.1182/bloodadvances.2019000145. PubMed 31332045 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Mar 2015, 40 months.

Results were first posted in Oct 2019, 4 years 7 months after primary completion.

Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2011
First posted
Jun 27, 2011
StartActual
Nov 2011
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Oct 29, 2019
Last update
Feb 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01380535
Lead sponsor
Mallinckrodt
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Nov 2011
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Oct 29, 2019
Last update
Feb 19, 2020

Study contacts

Global Clinical Leader
study director · Mallinckrodt

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion